Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
Indicate by check mark whether the registrant is an emerging
growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Liquidia Technologies, Inc. (the “Company”), a late-stage
clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT®
technology, today announced it has postponed its special meeting of stockholders, originally scheduled for October 21, 2020 (the
“Special Meeting”).
On October 16, 2020, the Company received an unsolicited offer
to enter into a License Agreement for the Company’s LIQ861 product candidate (the “Offer”). The Offer is also
conditioned upon the Company terminating the Agreement and Plan of Merger, dated as of June 29, 2020, by and among the Company,
RareGen, LLC, Liquidia Corporation, Gemini Merger Sub I, Inc., Gemini Merger Sub II, LLC, and PBM RG Holdings, LLC (the “Merger
Agreement”). The Company’s Board of Directors is evaluating whether the Offer constitutes a “Superior Proposal”
pursuant to the Merger Agreement, and has decided to postpone the Special Meeting to provide additional time for the Company’s
Board of Directors to fully consider all relevant factors with respect to the Offer. The Company will provide additional disclosure
upon the conclusion of its review and provide additional information regarding a date for the Special Meeting, if applicable.
A copy of the press release announcing the postponement of the
Special Meeting is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01
|
Financial Statements and Exhibits.
|
(d)
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
October 19, 2020
|
Liquidia Technologies, Inc.
|
|
|
|
|
|
By:
|
/s/ Steven Bariahtaris
|
|
|
Name:
|
Steven Bariahtaris
|
|
|
Title:
|
Interim Chief Financial Officer
|
Exhibit 99.1
Liquidia Technologies, Inc.
419 Davis Drive, Suite 100
Morrisville, NC 27560
MEDIA RELEASE
www.liquidia.com
Liquidia Announces Postponement of Special
Meeting of Stockholders
RESEARCH TRIANGLE PARK, N.C., October 19,
2020 - Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused
on the development and commercialization of novel products using its proprietary PRINT® technology, today
announced that it has postponed the special meeting of stockholders, originally scheduled for October 21, 2020.
On October 16, 2020, Liquidia
received an unsolicited offer to enter into a License Agreement for the Company’s LIQ861 product candidate (the “Offer”).
The Offer is also conditioned upon Liquidia terminating the Agreement and Plan of Merger, dated as of June 29, 2020, by and
among the Company, RareGen, LLC, Liquidia Corporation, Gemini Merger Sub I, Inc., Gemini Merger Sub II, LLC, and PBM RG Holdings,
LLC (the “Merger Agreement”). The Liquidia Board of Directors is evaluating whether the Offer constitutes a “Superior
Proposal” pursuant to the Merger Agreement and has decided to postpone the Special Meeting to provide additional time to
fully consider all relevant factors with respect to the Offer.
The Company will provide additional
disclosure upon the conclusion of its review and provide additional information regarding a date for the Special Meeting, if applicable.
About Liquidia
Liquidia is a late-stage clinical
biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT®
technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production
of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is
focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment
of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. Liquidia is headquartered
in Research Triangle Park, NC. For more information, please visit www.liquidia.com.
Liquidia Technologies, Inc.
419 Davis Drive, Suite 100
Morrisville, NC 27560
MEDIA RELEASE
www.liquidia.com
Cautionary Statements Regarding
Forward-Looking Statements
This press release may include forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press
release other than statements of historical facts, including statements regarding our future results of operations and financial
position, our strategic and financial initiatives, our business strategy and plans and our objectives for future operations, are
forward-looking statements. Such forward-looking statements, including statements regarding clinical trials, clinical studies
and other clinical work (including the funding therefor, anticipated patient enrollment, safety data, study data, trial outcomes,
timing or associated costs), regulatory applications and related timelines, including potential U.S. Food and Drug Administration (FDA)
approval of the New Drug Application (NDA) for LIQ861, the timeline or outcome related to our patent litigation pending in the U.S.
District Court for the District of Delaware or its inter partes review with the Patent Trial and Appeal
Board, the issuance of patents by the USPTO and our ability to execute on our strategic or financial initiatives, involve significant
risks and uncertainties and actual results could differ materially from those expressed or implied herein. The words “anticipate,”
“believe,” “continue,” “could,” “estimate,” “expect,” “intend,”
“may,” “plan,” “potential,” “predict,” “project,” “should,”
“target,” “would,” and similar expressions are intended to identify forward-looking statements. We have
based these forward-looking statements largely on our current expectations and projections about future events and financial trends
that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business
operations and objectives and financial needs. These forward-looking statements are subject to a number of risks discussed in
our and Liquidia Corporation’s filings with the Securities and Exchange Commission, including the risk that our proposed
acquisition of RareGen, LLC is not consummated or that the expected benefits and synergies from the proposed acquisition
are not realized, the impact of the coronavirus (COVID-19) outbreak on our company and our financial condition and results of
operations, as well as a number of uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing
environment and our industry has inherent risks. New risks emerge from time to time. It is not possible for our management to
predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination
of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make.
In light of these risks, uncertainties and assumptions, the future events discussed in this press release may not occur and actual
results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Nothing in
this press release should be regarded as a representation by any person that these goals will be achieved, and we undertake no
duty to update our goals or to update or alter any forward-looking statements, whether as a result of new information, future
events or otherwise.
Contact Information
Media:
Michael Parks
Corporate Communications
484.356.7105
michael.parks@liquidia.com
Investors:
Jason Adair
Vice President, Corporate Development and Strategy
919.328.4400
jason.adair@liquidia.com